School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Department of Otolaryngology-Head and Neck Surgery, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Laryngoscope. 2023 Jul;133(7):1722-1725. doi: 10.1002/lary.30395. Epub 2022 Sep 13.
To investigate how often patients are diagnosed with new-onset tinnitus within 21 days after COVID-19 vaccination in comparison to after three other common vaccinations: influenza, Tdap (tetanus, diphtheria, and acellular pertussis), and polysaccharide pneumococcus.
The TriNetX Analytics Network, a federated health research network that aggregates the de-identified electronic health record (EHR) data of over 78 million patients, was queried for patients receiving each vaccination. Instances of new-onset tinnitus within 21 days of vaccination were recorded and reported.
Out of 2,575,235 patients receiving a first dose of the mRNA COVID-19 vaccine without any prior tinnitus diagnosis, 0.038% (95% CI: 0.036%-0.041%) of patients had a new diagnosis of tinnitus within 21 days. There was a higher risk of a new tinnitus diagnosis after the influenza vaccine (RR: 1.95, 95% CI: 1.72-2.21), Tdap vaccine (RR: 2.36, 95% CI: 1.93-2.89), and pneumococcal vaccine (RR: 1.97, 95% CI: 1.48-2.64) than after the first dose of the COVID-19 vaccine. There was a lower risk of a new tinnitus diagnosis after the second dose of COVID-19 than after the first dose (RR: 0.80, 95% CI: 0.71-0.91).
The rate of newly diagnosed tinnitus acutely after the first dose of the COVID-19 vaccine is very low. There was a higher risk of newly diagnosed tinnitus after influenza, Tdap, and pneumococcal vaccinations than after the COVID-19 vaccine. The present findings can help to address COVID-19 vaccine hesitancy during the ongoing pandemic.
Level 3 Laryngoscope, 133:1722-1725, 2023.
调查新冠病毒疫苗接种后 21 天内新诊断出耳鸣的患者比例与流感、Tdap(破伤风、白喉和无细胞百日咳)和多糖肺炎球菌疫苗接种后相比的情况。
TriNetX 分析网络是一个联合了超过 7800 万患者去识别电子健康记录(EHR)数据的联邦健康研究网络,我们对接受每种疫苗接种的患者进行了查询。记录并报告了疫苗接种后 21 天内新发耳鸣的病例。
在 2575235 名接受第一剂 mRNA 新冠病毒疫苗接种且无任何先前耳鸣诊断的患者中,0.038%(95%置信区间:0.036%-0.041%)的患者在 21 天内被新诊断出耳鸣。与接种第一剂新冠病毒疫苗相比,接种流感疫苗(RR:1.95,95%置信区间:1.72-2.21)、Tdap 疫苗(RR:2.36,95%置信区间:1.93-2.89)和肺炎球菌疫苗(RR:1.97,95%置信区间:1.48-2.64)后新发耳鸣的风险更高。与接种第一剂相比,接种第二剂新冠病毒疫苗后新发耳鸣的风险较低(RR:0.80,95%置信区间:0.71-0.91)。
第一剂新冠病毒疫苗接种后急性新发耳鸣的比例非常低。与新冠病毒疫苗相比,接种流感、Tdap 和肺炎球菌疫苗后新发耳鸣的风险更高。本研究结果有助于解决当前大流行期间对新冠病毒疫苗的犹豫。
3 级喉镜,133:1722-1725,2023 年。